Can a common diabetes pill save transplanted kidneys?
NCT ID NCT07555106
First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tests whether dapagliflozin, a drug used for diabetes, can help protect kidney function in people who received a kidney transplant from a living donor. About 54 adults will take the drug daily for a year, starting one month after transplant, and their kidney health will be compared to those receiving standard care. The goal is to see if the drug can slow kidney decline and reduce damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universidad de Guadalajara
Guadalajara, Jalisco, 44250, Mexico
Conditions
Explore the condition pages connected to this study.